Anti-cancer drugs - JoVE Visualize

Showing results (291-300 of 4,634) with videos related to

Pageof 464

Sort By:

Anti-Cancer Drugs|June 23, 1999

Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusionC Focan, F Levi, F Kreutz, et al.

Anti-Cancer Drugs|June 23, 1999

Methotrexate-albumin conjugate causes tumor growth delay in Dunning R3327 HI prostate cancer-bearing ratsG Stehle, A Wunder, H H Schrenk, et al.

Anti-Cancer Drugs|June 23, 1999

Cytotoxic effects of two gamma linoleic salts (lithium gammalinolenate or meglumine gammalinolenate) alone or associated with a nitrosourea: an experimental study on human glioblastoma cell linesK Ilc, J M Ferrero, J L Fischel, et al.

Anti-Cancer Drugs|May 18, 1999

Activity of MKT 077, a rhodacyanine dye, against human tumor colony-forming unitsT Petit, E Izbicka, R A Lawrence, et al.

Anti-Cancer Drugs|May 18, 1999

Modulation of 9-nitrocamptothecin-induced apoptosis by hyperthermia in human leukemia HL-60 cellsP Pantazis, D Chatterjee, Z Han, et al.

Anti-Cancer Drugs|May 18, 1999

Metabolic studies of [18F-alpha-methyl]tyrosine in mice bearing colorectal carcinoma LS-180K Tomiyoshi, T Inoue, T Higuchi, et al.

Anti-Cancer Drugs|September 7, 1999

Variable intrinsic sensitivity of human tumor cell lines to raltitrexed (Tomudex) and folylpolyglutamate synthetase activityS Chéradame, M Chazal, J L Fischel, et al.

Anti-Cancer Drugs|January 12, 2000

Compatibility and stability of aplidine, a novel marine-derived depsipeptide antitumor agent, in infusion devices, and its hemolytic and precipitation potential upon i.v. administrationB Nuijen, M Bouma, R E Henrar, et al.

Anti-Cancer Drugs|January 12, 2000

Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumorsR A Newman, J Kim, B M Newman, et al.

Anti-Cancer Drugs|January 12, 2000

Synthesis and cytotoxic activity of N-(2-chloroethyl)-N-nitroureas and N-(2-chloroethyl)-N-nitrocarbamatesJ Botyánszki, J Bódi, I J Stratford, et al.

Pageof 464

Showing results (291-300 of 4,634) with videos related to

Sort By:

Pageof 464

Anti-Cancer Drugs|June 23, 1999

Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusionC Focan, F Levi, F Kreutz, et al.

Anti-Cancer Drugs|June 23, 1999

Methotrexate-albumin conjugate causes tumor growth delay in Dunning R3327 HI prostate cancer-bearing ratsG Stehle, A Wunder, H H Schrenk, et al.

Anti-Cancer Drugs|June 23, 1999

Cytotoxic effects of two gamma linoleic salts (lithium gammalinolenate or meglumine gammalinolenate) alone or associated with a nitrosourea: an experimental study on human glioblastoma cell linesK Ilc, J M Ferrero, J L Fischel, et al.

Anti-Cancer Drugs|May 18, 1999

Activity of MKT 077, a rhodacyanine dye, against human tumor colony-forming unitsT Petit, E Izbicka, R A Lawrence, et al.

Anti-Cancer Drugs|May 18, 1999

Modulation of 9-nitrocamptothecin-induced apoptosis by hyperthermia in human leukemia HL-60 cellsP Pantazis, D Chatterjee, Z Han, et al.

Anti-Cancer Drugs|May 18, 1999

Metabolic studies of [18F-alpha-methyl]tyrosine in mice bearing colorectal carcinoma LS-180K Tomiyoshi, T Inoue, T Higuchi, et al.

Anti-Cancer Drugs|September 7, 1999

Variable intrinsic sensitivity of human tumor cell lines to raltitrexed (Tomudex) and folylpolyglutamate synthetase activityS Chéradame, M Chazal, J L Fischel, et al.

Anti-Cancer Drugs|January 12, 2000

Compatibility and stability of aplidine, a novel marine-derived depsipeptide antitumor agent, in infusion devices, and its hemolytic and precipitation potential upon i.v. administrationB Nuijen, M Bouma, R E Henrar, et al.

Anti-Cancer Drugs|January 12, 2000

Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumorsR A Newman, J Kim, B M Newman, et al.

Anti-Cancer Drugs|January 12, 2000

Synthesis and cytotoxic activity of N-(2-chloroethyl)-N-nitroureas and N-(2-chloroethyl)-N-nitrocarbamatesJ Botyánszki, J Bódi, I J Stratford, et al.

Pageof 464